Dr. Byrd on Impact of Ibrutinib on Patients With CLL

John C. Byrd, MD
Published: Wednesday, Sep 06, 2017



John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the long-term impact that ibrutinib (Imbruvica) has on patients with chronic lymphocytic leukemia (CLL).

Ohio State University have had to add a survivorship clinic to their institution due to the number of patients who have participated in ibrutinib clinical trials, including RESONATE. Moreover, Byrd explains, many of these patients would likely not have survived if they did not receive treatment with ibrutinib.

Hearing patients' stories and seeing them continue to live life magnifies the effect of ibrutinib on patients with CLL, he adds.
SELECTED
LANGUAGE


John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the long-term impact that ibrutinib (Imbruvica) has on patients with chronic lymphocytic leukemia (CLL).

Ohio State University have had to add a survivorship clinic to their institution due to the number of patients who have participated in ibrutinib clinical trials, including RESONATE. Moreover, Byrd explains, many of these patients would likely not have survived if they did not receive treatment with ibrutinib.

Hearing patients' stories and seeing them continue to live life magnifies the effect of ibrutinib on patients with CLL, he adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x